相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
John J. Zaknun et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Treatment with the Radiolabelled Somatostatin Analog 177Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
Maddalena Sansovini et al.
NEUROENDOCRINOLOGY (2013)
Does the Pretherapeutic Tumor SUV in 68Ga DOTATOC PET Predict the Absorbed Dose of 177Lu Octreotate?
Samer Ezziddin et al.
CLINICAL NUCLEAR MEDICINE (2012)
Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine: a clarification
Alexander Kroiss et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy
Samer Ezziddin et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax
Christian Boy et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
Lisa Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers
Anna Imhof et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors
Alexander R. Haug et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Response and Long-Term Control of Bone Metastases After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
Samer Ezziddin et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
Dik J. Kwekkeboom et al.
ENDOCRINE-RELATED CANCER (2010)
Internalized Somatostatin Receptor Subtype 2 in Neuroendocrine Tumors of Octreotide-Treated Patients
Jean Claude Reubi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
In vivo binding of [Ga-68]-DOTATOC to somatostatin receptors in neuroendocrine tumours - impact of peptide mass
Irina Velikyan et al.
NUCLEAR MEDICINE AND BIOLOGY (2010)
Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
Dik J. Kwekkeboom et al.
SEMINARS IN NUCLEAR MEDICINE (2010)
Differential Effects of Octreotide and Pasireotide on Somatostatin Receptor Internalization and Trafficking in Vitro
Sarah Lesche et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Highly Efficient In Vivo Agonist-Induced Internalization of sst(2) Receptors in Somatostatin Target Tissues
Bea Waser et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs
Dik J. Kwekkeboom et al.
NEUROENDOCRINOLOGY (2009)
Processing of generator-produced 68Ga for medical application
Konstantin P. Zhernosekov et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2
Nadder Sharif et al.
ENDOCRINOLOGY (2007)
68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors:: Comparison with somatostatin receptor scintigraphy and CT
Michael Gabriel et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Peptide receptor radionuclide therapy
Flavio Forrer et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Peptide receptors as molecular targets for cancer diagnosis and therapy
JC Reubi
ENDOCRINE REVIEWS (2003)
Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities
WAP Breeman et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
DJ Kwekkeboom et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity
WAP Breeman et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use
JC Reubi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2000)
分享论文
